Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Use of Antiemetic Agents in Acute Gastroenteritis 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease
Your Article Summary
See Latest ArticlesThe value of drugs for obesity in the management of cardiovascular risk factors
Sang Thrombose Vaisseaux, 11/04/09
Czernichow S et al. – Clinical trials show that the expected weight loss is 3 to 4 Kg compared with placebo. In addition, orlistat should improve blood sugar and lipid levels and reduce blood pressure. Sibutramine increases HDL cholesterol, decreases triglycerides but increases the blood pressure and heart rate. A trial is underway to study the impact of these adverse effects in subjects at high cardiovascular risk. Therefore, the field for the development of new drugs for treating overweight and obesity remains wide open.
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Novel Therapies for Pemphigus Vulgaris: An Overview
Drugs & Aging, 09/21/09
New Anticoagulants in Atrial Fibrillation
Seminars in Thrombosis and Hemostasis, 10/02/09
Antithrombotic medication for stroke prevention
Expert Review of Cardiovascular Therapy , 10/20/09
Article Search
Sponsor